Form 4: Adaptive Biotechnologies CSO Sells 10,000 Shares

Adaptive Biotechnologies' Chief Scientific Officer, Harlan S. Robins, sold 10,000 shares of common stock for a weighted average price of $16.44 per share.

Summary

• Harlan S. Robins, Chief Scientific Officer of Adaptive Biotechnologies Corp (ADPT), sold 10,000 shares of common stock.
• The transaction occurred on January 6, 2026, at a weighted average price of $16.44 per share.
• The shares were sold in multiple transactions at prices ranging from $16.05 to $16.78, inclusive.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.
• Following the transaction, Robins beneficially owns 1,222,312 shares directly.

Sentiment

Score: 4

Explanation: The sale of shares by a Chief Scientific Officer, even under a Rule 10b5-1 plan, can be perceived as a minor negative signal by the market, though the pre-planned nature reduces immediate concern.

Negatives

• An insider sale of 10,000 shares by the Chief Scientific Officer, even under a Rule 10b5-1 plan, could be perceived as a minor negative signal by the market, potentially indicating a need for liquidity or diversification rather than a strong vote of confidence.

Future Outlook

N/A

Industry Context

N/A

Stakeholder Impact

• Shareholders: May interpret the insider sale as a slight negative signal, potentially impacting investor confidence, although the pre-planned nature mitigates some concern.

Key Dates

Recommendation

The sale of 10,000 shares by the Chief Scientific Officer, while notable, was executed under a pre-arranged Rule 10b5-1 trading plan, which suggests it's for personal financial planning rather than a reaction to new negative information. This single transaction, representing a small fraction of the total shares beneficially owned (1,222,312 shares remaining), is unlikely to fundamentally alter the company's long-term prospects or warrant a change from a 'hold' position without further context or a pattern of significant insider selling.

Keywords

Adaptive Biotechnologies, ADPT, Insider Trading, Form 4, Harlan S. Robins, Stock Sale, Chief Scientific Officer, Rule 10b5-1